BRAF and Ehlers-Danlos syndrome, musculocontractural type: BRAF mutations have been involved in a greater clinical aggressiveness, as well as TERT mutations, that are found in 7.5% of PTCs, 17.1% of FTCs, 29.0% of PDTCs and 33.3% of ATCs [27].